• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

J&J’s Janssen wins $45m BARDA contract for Ebola vaccine dev

October 2, 2017 By Fink Densford

Janssen

Johnson & Johnson (NYSE:JNJ) said today that its Janssen Pharmaceutical subsidiary Janssen Vaccines & Prevention B.V received a $44.7 million award and collaborative partnership from the US Biomedical Advanced Research and Development Authority to support its development of an investigational Ebola vaccine regimen.

The deal comes with an option for BARDA to provide additional funding over 5 years to help develop and potentially license the Ebola vaccine candidate, J&J said. The vaccine includes an initial dose to prime the immune system to develop immune responses, followed by a booster dose to strengthen and optimize the duration of the response, the company said.

“Developing effective Ebola vaccines will be critical if we are to combat potential future outbreaks and protect frontline healthcare workers as well as the families and friends of Ebola victims. This award underscores the importance of public-private partnerships in tackling global health challenges. Our effort to accelerate the development of Janssen’s Ebola vaccine candidate to date would not have been possible without support from a wide range of global funders, including the National Institutes of Health, Europe’s Innovative Medicines Initiative, and the U.S. Department of Defense,” J&J chief scientific officer Dr. Paul Stoffels said in a prepared statement.

Janssen said it 1st began working on an Ebola vaccine in collaboration with the NIH, with development accelerating during the 2014-2016 outbreak in West Africa through an additional commitment of $200 million from the company and an additional $117m (EU €100 million) in grants from the IMI/European Commission.

“History teaches us that Ebola will return – as we recently saw in the Democratic Republic of Congo. These ongoing outbreaks demonstrate the importance of disease surveillance and management, the value of strong health systems, and the need to finish the job of developing safe and effective vaccines to help protect communities and prevent a resurgence of the virus. It is within our power, working in partnership, to prevent a future pandemic,” Peter Piot of the London School of Hygiene & Tropical Medicine said in a prepared release.

A total of 11 phase 1, 2 and 3 clinical studies of the vaccine are underway across the US, Africa and Europe, the company said.

“Never before has Johnson & Johnson mobilized resources so rapidly to accelerate a vaccine candidate – supporting the initiation of multiple clinical trials across 3 continents in just 1 year. Thankfully, the Ebola crisis in West Africa is over, but we and other vaccine manufacturers remain determined to ensure that Ebola vaccines are successfully developed and made available to the world,” Janssen global head of infectious diseases & vaccines Dr. Johan Van Hoof said in a press release.

Filed Under: Business/Financial News, Featured, Funding Roundup, Research & Development Tagged With: Janssen Pharmaceuticals, johnsonandjohnson

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS